Background: Basal cell adenocarcinoma is an uncommon basaloid malignancy seen most frequently in the salivary glands. Due to the rarity of this tumor data on survival and treatment is limited. Aim: The aim of this study was to examine factors affecting survival in patients with basal cell adenocarcinoma. Methods: The 1973-2014 Surveillance, Epidemiology, and End Results database was queried for patients with basal cell adenocarcinoma. The data was analyzed for tumor staging, site, and demographic characteristics. The Kaplan-Meier model was used to estimate actuarial survival. Results: A total of 247 patients were identified with complete TNM staging data. White patients represented 83.0% of the total (205/247). Patients were 51.0% female (126/247) and 49.0% male (121/247). Overall 5- and 10-year survival was 80.6% and 65.0%, respectively. Mean survival time was 100.8 months. Parotid gland was the most common site, followed by skin, submandibular gland, mouth/oral cavity, and vulva. Most patients were stage T1 or T2. Distant metastasis was present in only 1.6% (4/247) patients. 93.1% (230/247) of patients had surgical treatment. On univariate analysis T stage, primary tumor site, presence of distant metastasis, age, sex, and AJCC stage significantly affected survival. On multivariate analysis age and T stage remained significant. Conclusions: Basal cell adenocarcinoma is a basaloid malignancy most frequently seen in the parotid gland. The survival rate is high, and nodal and distant metastasis rates are low. Surgery is the mainstay of treatment, and T and M stage, primary site, age, sex, and AJCC stage all significantly affected survival.